Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) were up 10.4% during trading on Tuesday . The company traded as high as $14.65 and last traded at $14.00, with a volume of 1,183,761 shares traded. The stock had previously closed at $12.68.

A number of analysts have recently commented on AQXP shares. Jefferies Group boosted their target price on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Finally, Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Aquinox Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $19.86.

The stock’s market cap is $234.60 million. The firm’s 50-day moving average is $10.77 and its 200-day moving average is $8.69.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. Equities research analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.11) earnings per share for the current fiscal year.

In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of Aquinox Pharmaceuticals stock in a transaction on Tuesday, September 20th. The shares were purchased at an average cost of $12.25 per share, with a total value of $34,099,161.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors boosted its position in Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock worth $1,514,000 after buying an additional 3,977 shares during the last quarter. BlackRock Advisors LLC boosted its position in Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock worth $2,678,000 after buying an additional 8,280 shares during the last quarter. Vanguard Group Inc. boosted its position in Aquinox Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 110,529 shares of the company’s stock worth $731,000 after buying an additional 2,197 shares during the last quarter. Royce & Associates LP boosted its position in Aquinox Pharmaceuticals by 89.9% in the second quarter. Royce & Associates LP now owns 182,622 shares of the company’s stock worth $1,209,000 after buying an additional 86,455 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in Aquinox Pharmaceuticals during the second quarter worth approximately $166,000. 89.41% of the stock is currently owned by institutional investors and hedge funds.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.